ABT

Abbott Laboratories reported new data from the Beta-CORRECT study showing higher sensitivity for its Oncodetect test in detecting colorectal cancer recurrence using circulating tumor DNA. The study was presented at ESMO 2026 and highlights improved detection of low-level tumor DNA after surgery.

108-Page Report Examines the Shift to Leadless and MRI-Compatible Devices as Rising Arrhythmia Prevalence Drives Demand, While High Procedure Costs, Strict Approvals and Cybersecurity Risks Weigh on GrowthDublin, Oct. 23, 2026 (GLOBE NEWSWIRE) -- "Pacemakers: Global Markets" has been added to ResearchAndMarkets.com's offering.

The headline asks whether Abbott stock is about to rebound, but no additional details are provided.

Wells Fargo analyst Larry Biegelsen keeps an Overweight rating on Abbott Laboratories and raised its price target from $119 to $120. The update reflects the bank’s view of the company’s prospects.

Abbott presented new Beta-CORRECT data at the ESMO Congress, showing a 30% increase in sensitivity for detecting colorectal cancer recurrence within two years of surgery. The data come from the Oncodetect® whole-genome sequencing assay.

FORT MILL, S.C, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, a wholly owned subsidiary of Flyte Aviation, Inc. (NYSE American: VJET), today announced the first published comparative study evaluating its LockeT suture retention device against a traditional internal vascular closure device (VCD) following large bore venous access.